• Something wrong with this record ?

The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis

M. Rehak, J. Rehak, M. Müller, S. Faude, F. Faude, A. Siegemund, V. Krcova, L. Slavik, D. Hasenclever, M. Scholz, P. Wiedemann,

. 2008 ; 99 (5) : 925-929. [pub] -

Language English Country Germany

Document type Journal Article, Meta-Analysis, Multicenter Study

Several small case-control studies have investigated whether factor V Leiden (FVL) is a risk factor for retinal vein occlusion (RVO) and generated conflicting data. To clarify this question we performed a large two-centre case-control study and a meta-analysis of published studies. Two hundred seven consecutive patients with RVO and a control group of 150 subjects were screened between 1996 and 2006. A systematic meta-analysis was done combining our study with further 17 published European case-control studies. APC resistance was detected in 16 out of 207 (7.7%) patients and eight out of 150 (5.3%) controls. The odds ratio (OR) estimated was 1.49 with a (non-significant) 95% confidence interval (CI) of 0.62-3.57. The meta-analysis including 18 studies with a total of 1,748 patients and 2,716 controls showed a significantly higher prevalence of FVL in patients with RVO compared to healthy controls (combined OR 1.66; 95% CI 1.19-2.32). All single studies combined in the meta-analysis were too small to reliably detect the effect individually. This explains the seemingly contradictory data in the literature. In conclusion, the prevalence of APC resistance (and FVL) is increased in patients with RVO compared to controls, but the effect is only moderate. Therefore, there is no indication for general screening of factor V mutation in all patients with RVO. We recommend this test to be performed in patients older than 50 years with an additional history of thromboembolic event and in younger patients without general risk factors like hypertension.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20014399
003      
CZ-PrNML
005      
20200921152842.0
007      
ta
008      
200918s2008 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1160/TH07-11-0658 $2 doi
035    __
$a (PubMed)18449423
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Rehak, Matus $u Department of Ophthalmology, University Hospital Leipzig, Liebigstrasse 10-14, 04103 Leipzig, Germany.
245    14
$a The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis / $c M. Rehak, J. Rehak, M. Müller, S. Faude, F. Faude, A. Siegemund, V. Krcova, L. Slavik, D. Hasenclever, M. Scholz, P. Wiedemann,
520    9_
$a Several small case-control studies have investigated whether factor V Leiden (FVL) is a risk factor for retinal vein occlusion (RVO) and generated conflicting data. To clarify this question we performed a large two-centre case-control study and a meta-analysis of published studies. Two hundred seven consecutive patients with RVO and a control group of 150 subjects were screened between 1996 and 2006. A systematic meta-analysis was done combining our study with further 17 published European case-control studies. APC resistance was detected in 16 out of 207 (7.7%) patients and eight out of 150 (5.3%) controls. The odds ratio (OR) estimated was 1.49 with a (non-significant) 95% confidence interval (CI) of 0.62-3.57. The meta-analysis including 18 studies with a total of 1,748 patients and 2,716 controls showed a significantly higher prevalence of FVL in patients with RVO compared to healthy controls (combined OR 1.66; 95% CI 1.19-2.32). All single studies combined in the meta-analysis were too small to reliably detect the effect individually. This explains the seemingly contradictory data in the literature. In conclusion, the prevalence of APC resistance (and FVL) is increased in patients with RVO compared to controls, but the effect is only moderate. Therefore, there is no indication for general screening of factor V mutation in all patients with RVO. We recommend this test to be performed in patients older than 50 years with an additional history of thromboembolic event and in younger patients without general risk factors like hypertension.
650    _2
$a rezistence k aktivovanému proteinu C $x komplikace $x epidemiologie $x genetika $7 D020016
650    _2
$a dospělí $7 D000328
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a faktor V $x genetika $7 D005165
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a genetické testování $7 D005820
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a odds ratio $7 D016017
650    _2
$a prevalence $7 D015995
650    _2
$a okluze retinální žíly $x epidemiologie $x etiologie $x genetika $7 D012170
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a tromboembolie $x komplikace $7 D013923
651    _2
$a Česká republika $7 D018153
651    _2
$a Německo $7 D005858
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Rehak, Jiri
700    1_
$a Müller, Marc
700    1_
$a Faude, Susanne
700    1_
$a Faude, Frank
700    1_
$a Siegemund, Annelie
700    1_
$a Krcova, Vera
700    1_
$a Slavik, Ludek
700    1_
$a Hasenclever, Dirk
700    1_
$a Scholz, Markus
700    1_
$a Wiedemann, Peter
773    0_
$w MED00004517 $t Thrombosis and haemostasis $x 0340-6245 $g Roč. 99, č. 5 (2008), s. 925-929
856    41
$u https://pubmed.ncbi.nlm.nih.gov/18449423 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200918 $b ABA008
991    __
$a 20200921152841 $b ABA008
999    __
$a ok $b bmc $g 1565251 $s 1104557
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2008 $b 99 $c 5 $d 925-929 $e - $i 0340-6245 $m Thrombosis and haemostasis $n Thromb Haemost $x MED00004517
LZP    __
$a Pubmed-20200918

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...